
A new boxed warning has been added to the labeling for five gadolinium-based contrast agents used to improve the visibility of internal structures during MRI scans. This came after the FDA received reports of the risk of developing nephrogenic systemic fibrosis (NSF), a potentially fatal disease causing thickening of the skin and connective tissues that inhibits their movement.